Aytu Biopharma (AYTU) Current Assets (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Current Assets data on file, last reported at $67.3 million in Q1 2026.

• Current Assets for Q1 2026 came in at $67.3 million, down 7.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.3 million (down 7.15% YoY), and the FY2025 annual result was $79.2 million, up 27.93% from the prior year.
• Current Assets retreated to $67.3 million in Q1 2026 per AYTU's latest filing, from $76.2 million in the prior quarter.
• Over five years, Current Assets peaked at $81.1 million in Q3 2025 and troughed at $59.9 million in Q2 2022.
• A 5-year average of $71.1 million and a median of $71.4 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets plunged 43.05% in 2022, then surged 33.54% in 2025.
• A 5-year view of Current Assets shows it stood at $70.6 million in 2022, then rose by 1.08% to $71.4 million in 2023, then declined by 11.65% to $63.1 million in 2024, then increased by 20.92% to $76.2 million in 2025, then decreased by 11.69% to $67.3 million in 2026.
• Business Quant data shows AYTU's Current Assets at $67.3 million in Q1 2026, $76.2 million in Q4 2025, and $81.1 million in Q3 2025.